Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $0.46 per share which missed the analyst consensus estimate of $0.63 by 26.4 percent. This is a 50 percent decrease over earnings of $0.92 per share from the same period last year. The company reported quarterly sales of $875.000 million which beat the analyst consensus estimate of $827.969 million by 5.68 percent. This is a 17.14 percent increase over sales of $747.000 million the same period last year.